RECURSION PHARMACEUTICALS, INC. (RXRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 15M 30M 45M Q3 '24: 26.1M Q4 '24: 4.5M Q1 '25: 14.7M Q2 '25: 19.2M Q3 '25: 5.2M Q4 '25: 35.5M Q1 '26: 6.5M Q2 '26: 7.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

-16M -8M 0 8M 16M 24M Q3 '24: 14M Q4 '24: -8.2M Q1 '25: -7.1M Q2 '25: -938K Q3 '25: -9.5M Q4 '25: 21.3M Q1 '26: -6M Q2 '26: -3.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '24: -98.4M Q4 '24: -183.8M Q1 '25: -191.4M Q2 '25: -176.2M Q3 '25: -172.2M Q4 '25: -108.3M Q1 '26: -128.5M Q2 '26: -135M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '24: -95.8M Q4 '24: -178.9M Q1 '25: -202.5M Q2 '25: -171.9M Q3 '25: -162.3M Q4 '25: -108.1M Q1 '26: -117.5M Q2 '26: -131M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 8M 16M 24M Q3 '24: 12.1M Q4 '24: 12.8M Q1 '25: 21.8M Q2 '25: 20.2M Q3 '25: 14.7M Q4 '25: 14.3M Q1 '26: 12.5M Q2 '26: 11.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '24: -59.2M Q4 '24: -115.4M Q1 '25: -132M Q2 '25: -76.4M Q3 '25: -117.4M Q4 '25: -46.1M Q1 '26: -81.1M Q2 '26: -105.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '24: -63.8M Q4 '24: -116.7M Q1 '25: -133.8M Q2 '25: -79.6M Q3 '25: -117.6M Q4 '25: -47.3M Q1 '26: -81.4M Q2 '26: -106M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 200M 400M 600M Q1 '24: 236M Q2 '24: 242.2M Q3 '24: 282.6M Q1 '25: 402.8M Q2 '25: 417.4M Q3 '25: 447M Q1 '26: 529.3M Q2 '26: 532.5M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.10 -1.40 -0.70 0.00 0.70 1.40 2.10 Q3 '24: -1.55 Q4 '24: -1.70 Q1 '25: -1.81 Q2 '25: -1.82 Q3 '25: -1.84 Q4 '25: -1.44 Q1 '26: -1.16 Q2 '26: -1.00 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.